The purpose of this Paul Calabresi Award in Clinical Oncology Research (PCACOR) is to prepare highly qualified cancer clinical researchers called Scholars who can independently design, manage and complete cancer clinical trials by learning to communicate and coordinate with multidisciplinary teams of clinical and basic scientists using state-of-the-art laboratory analyses to personalize cancer treatment. Specific objectives are to: 1) Provide a flexible Individual Development Program for oncology medical doctors and Ph.D. clinicians (nurses, pharmacists, clinical psychologists, epidemiologists, oral surgeons) who have completed their clinical training and basic research scientists who are committed to a translational clinical cancer research career in an academic setting;2) Foster interdisciplinary training, communication and interaction through multiple mentoring of program scholars;3) Create an ongoing mentorship to the completed PCACOR Scholars to ensure their successful transition to clinical research independence. Strong clinical and basic science mentors provide exceptional training and role models in all oncology clinical disciplines as well in cancer basic science. A multidisciplinary Advisory Committee oversees the PCACOR directed by Program Leaders, Madeleine A. Kane, MD, Ph.D., Professor of Medical Oncology, and Andrew Thorburn, Ph.D., Professor and Chair, Department of Pharmacology, Deputy Director, UCCC. Training period lasts from two to seven years and includes Core requirements such as Responsible Conduct of Research and coursework provided by CCTSI Clinical Science Program and the UCD Graduate School. Each Scholar completes a basic science project and also designs at least one cancer clinical trial. Scholars submit an NIH style grant application within the last yea of training. The ultimate success is demonstrated by our track record. A total of fifteen junior faculty have trained as PCACOR Scholars, nine during the current funding period (out of 42 applications). Thirteen Scholars remain faculty members at University of Colorado Denver Anschutz Medical Campus (UCD-AMC);six have been promoted, all have multiple peer-reviewed publications, both clinical and basic science. Eight have obtained peer-reviewed funding from NIH, DOD ACS and/or Komen Foundation. All have designed at least one cancer clinical trial, and several PCACOR graduates lead national cancer clinical trials, cancer research training programs and clinical cancer research programs. Our PCACOR successfully produces the translational cancer clinical researchers of the future.

Public Health Relevance

The Paul Calabresi Award for Clinical Oncology Research trains translational clinical and basic cancer researchers who can work together to combine molecular methods with clinical information to personalize cancer clinical trials to improve the outcome for cancer patients with less toxicity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
2K12CA086913-12
Application #
8486241
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
2000-09-18
Project End
2018-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
12
Fiscal Year
2013
Total Cost
$1,017,211
Indirect Cost
$81,319
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Vaishnavi, Aria; Le, Anh T; Doebele, Robert C (2015) TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 5:25-34
Kiseljak-Vassiliades, Katja; Carlson, Nichole E; Borges, Manuel T et al. (2015) Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49:231-41
McCoach, Caroline E; Doebele, Robert C (2014) The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol 15:644-57
Motzer, Robert J; Jonasch, Eric; Agarwal, Neeraj et al. (2014) Kidney cancer, version 2.2014. J Natl Compr Canc Netw 12:175-82
Lam, Elaine T; Wong, Michael K K; Agarwal, Neeraj et al. (2014) Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother 37:360-5
Zheng, Fei-Meng; Long, Zi-Jie; Hou, Zhi-Jie et al. (2014) A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance. Mol Cancer Ther 13:1991-2003
Lauro, Christine; Macy, Margaret E; Zeitler, Philip et al. (2014) The relationship between thyroid dose and diagnosis of primary hypothyroidism in pediatric brain tumor patients receiving craniospinal irradiation. J Pediatr Endocrinol Metab 27:299-303
Aisner, Dara L; Nguyen, Teresa T; Paskulin, Diego D et al. (2014) ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res 12:111-8
Poonia, Seerat; Berge, Eamon M; Aisner, Dara L et al. (2014) EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy. Clin Lung Cancer 15:387-9
Le, Anh T; Doebele, Robert C (2014) The democratization of the oncogene. Cancer Discov 4:870-2

Showing the most recent 10 out of 45 publications